Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DBCOND0069854Male Urogenital Diseases Neoplasms

Metastatic Castration-Resistant Prostate Cancer (mCRPC) is the indication for 10 drugs in DrugBank. It is covered by 36 curated, structured indications.

Also known as: Metastatic Castration-Resistant Prostate Cancer · Castrate Refractory Metastatic Prostate Cancer (mCRPC) · Metastatic Castrate-resistant Prostate (CRPC) Cancer · mCRPC (Metastatic Castration-resistant Prostate Cancer) · Metastatic Castration-resistant Prostate Cancer (CRPC)
Classified under: Male Urogenital Diseases
Neoplasms
Urogenital Neoplasms
Indicated drugs: Abiraterone
Cabazitaxel
Enzalutamide
Lutetium Lu-177 vipivotide tetraxetan
Niraparib
Olaparib
Prednisolone
Prednisone
Radium Ra 223 dichloride
Rucaparib

Resolves to

Vocabularies

SNOMED CT459381000124106MedDRA10086830UMLSC4721208

What you can answer from here — as of September 26, 2026

10Indicated drugsWith each drug's targets and mechanism

Listed above

36Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

319Clinical trialsPhase, status and sponsor resolved per trial

8Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account